Effectiveness of drug and non-drug treatment of tobacco dependence among physicians and nurses

Мұқаба

Дәйексөз келтіру

Толық мәтін

Аннотация

Introduction. The article is devoted to assessing the effectiveness of drug and non-drug treatment of tobacco dependence in health care workers.

Material and methods. The study included 621 medical workers (237 men and 384 women) working in hospitals in Moscow, at the average age of 48.3 ± 5.6 years, including 207 doctors and 414 nurses. The medical workers were divided into 2 groups depending on the anti-smoking program used. The first group consisted of 316 medical workers who received non-drug methods of treatment: psychosocial support, using cognitive aspects; psychotherapy; breathing exercises; acupuncture; increase physical activity. The second group consisted of 305 medical workers who, in addition to non-drug methods (described above), received Varenicline treatment (Champix® - tablets) and, if necessary, nicotine replacement therapy.

Results. In medical workers from the 2nd group, besides non-pharmacological therapy, received the drug Varenicline, 195 out of 305 (64%) persons completely stopped smoking; In the 1st group of Medical workers receiving non-drug therapy, 177 out of 316 (56% ) cases completely quit smoking (OR= 1.40; 95% CI: 1.01-1.93; р=0.0423). 6 months after the end of the treatment program, in the first group 84 (26.7%) medical workers) in the 2nd group - 31 medical workers (10.2%) restarted smoking, (OR=3.02, 95% CI: 2.05-5.02; р<0.00001).

Conclusion. Thus, the antismoking program, including drug Varenicline and, if necessary, nicotine-replacement therapy, as well as non-drug effects, including psycho-social support; psychotherapy; breathing exercises; acupuncture; an increase in physical activity showed higher
efficacy compared with the antismoking program without Varenicline, moreover, high efficacy remained even after the treatment carried out for 6 months.

Негізгі сөздер

Авторлар туралы

Larisa Zakharova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Хат алмасуға жауапты Автор.
Email: gsnd9@mail.ru
ORCID iD: 0000-0002-3479-3753

MD, аssistant of the Department of Nursing, Institute of Psychological and Social Work of I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, 119991, Russian Federation.

e-mail: gsnd9@mail.ru

Ресей

A. Ibatov

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: noemail@neicon.ru
ORCID iD: 0000-0002-8388-4408
Ресей

Әдебиет тізімі

  1. Global Adult Tobacco Survey – GATS in Russian Federation, 2016. Available at: https://static-1.rosminzdrav.ru/system/attachments/attaches/000/036/485/original/GATS-краткий_отчет-рус.pdf?1511269867 (in Russian)
  2. WHO report on the global tobacco epidemic. Monitoring tobacco use and prevention policies. WHO; Geneva. 2017. 164 p. (NLM classification: WM 290). Available at: http://www.who.int/fctc/mediacentre/press-release/wntd-2017/en/ (in Russian)
  3. WHO report on the global tobacco Epidemic, 2013: warning about the dangers of tobacco. 2013. 213 p. Available at: http://apps.who.int/iris/bitstream/handle/10665/85380/9789244505878_rus.pdf;jsessionid=3239462D07680690FD8CCD3D87229C07?sequence=7 (in Russian)
  4. The concept of implementation of the state policy of combating tobacco consumption for 2010–2015. Available at: https://rg.ru/2011/02/08/antitabak-site-dok.html (in Russian)
  5. Kukes V.G., Marinin V.F., Gavrisyuk E.V. Vareniklin – preparat novogo pokoleniya dlya lecheniya tabachnoj zavisimosti. Klinicheskaya farmakologiya i terapiya. 2009; 18 (3): 1–5. (in Russian)
  6. Levshin V., Ladan B., Kutushev O., Lykov V. Gotovnost’ vracha k okazaniyu pomoshchi pacientu v otkaze ot kureniya. Vrach. 2011; 12: 40–3. (in Russian)
  7. Cahill K., Stevens S., Perera R. et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013; 5: CD009329. https://dx.doi.org/10.1002/14651858
  8. Hurt R.D., Ebbert J.O., Hays J.T. et al. Treating tobacco dependence in a medical setting. CA Cancer J Clin. 2009; 59 (5): 314–26.
  9. Hartmann-Boyce J., Stead L.F., Cahill K. et al. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. Addiction. 2014; 109 (9): 1414–25.
  10. Králíková E., Češka R., Pánková A. et al. Tobacco dependence treatment guidelines. Vnitr Lek. 2015; 61 (5 Suppl 1): 1S4–1S15.
  11. Králíková E., Kmetova A., Stepankova L. et al. Fifty-two-week continuous abstinence rates of smokers being treated with varenicline versus nicotine replacement therapy. Addiction. 2013; 108 (8): 1497–502.
  12. John R. Hughes varenicline as a cause of suicidal outcomes. Nicotine Tob Res. 2016; 18 (1): 2–9.
  13. Peto R., Lopez A.D., Boreham J. et al. Mortality from smoking in developed countries 1950–2005 (or later) (update March 2012). Oxford: Oxford University Press. Available at: http://www.ctsu.ox.ac.uk/~tobacco/
  14. The New Zealand Guidelines to Help People to Stop Smoking. Update September 14, 2014. ISBN 978–0-478–42809–4 (print), 978–0-478–42810–0 (online).
  15. Zwar N., Richmond R., Borland R. et al. Supporting smoking cessation: a guide for health professionals. The Royal Australian College of General Practitioners: Melbourne; 2011.
  16. Silagy C., Stead L.F. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2001; 2: CD000165.
  17. Silagy C., Lancaster T., Stead L. et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2002; 4: CD000146.
  18. Hughes J.R., Stead L.F., Hartmann-Boyce J. et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2014; 1: CD000031.
  19. West R., McNeill A., Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax. 2000; 55 (12): 987–99.
  20. Coe J.W., Brooks P.R., Vetelino M.G. et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005; 48 (10): 3474–7.
  21. Jorenby D.E., Hays J.T., Rigotti N.A. et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006; 296 (1): 56–63.
  22. Gonzales D., Rennard S.I., Nides M. et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustainedrelease bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006; 296 (1): 47–55.
  23. Rigotti N.A., Pipe A.L., Benowitz N.L. et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010; 121 (2): 221–9.
  24. Prochaska J.J., Hilton J.F. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ. 2012; 344: e2856.
  25. Mills E.J., Thorlund K., Eapen S., Wu P., Prochaska J.J. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation. 2014; 129 (1): 28–41.
  26. Tonstad S., Tonnesen P., Hajek P., Williams K.E., Billing C.B., Reeves K.R. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006; 296 (1): 64–71.
  27. Koegelenberg C.F., Noor F., Bateman E.D. et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA. 2014; 312 (2): 155–61.
  28. Ramon J.M., Morchon S., Baena A., Masuet-Aumatell C. Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation. BMC Med. 2014; 12: 172.
  29. Chang P.H., Chiang C.H., Ho W.C. et al. Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials. BMC Public Health. 2015; 15: 689.
  30. Ebbert J.O., Hughes J.R., West R.J. et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA. 2015; 313 (7): 687–94.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Zakharova L.A., Ibatov A.D., 2024


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 37884 от 02.10.2009.